This test requires a blood draw, so please ensure you can refer to a phlebotomist in the clients area before you order this test.

exacta is a comprehensive analysis of tumours that allows a therapy recommendation to be made for most cancer patients, based on clinical evidence and experience. Especially for rare solid tumours where no guidelines are available, in the advanced situation or for tumours that are difficult to treat, exacta is providing an advantage. 

exacta analyses millions of data points at the molecular level to identify all relevant targets for an individual therapy.

However, conventional ‘Standard of Care’ approach does not take into consideration the overall genetic architecture of a particular patient‘s tumour and consequently, patients could suffer due to failed therapies or aggressive relapse. It is, thus, imperative that the genetic architecture of the tumour is studied comprehensively before deciding the treatment plan, which has to be personalised to individual patients and their disease. exacta® helps unravel the driver mutations and pathways that are propelling a particular person’s cancer through multi-analyte and multi-coordinate analysis over 20.805 genes in the cancer genome. This analysis helps identify drugs that would be most effective for a particular solid tumour. exacta®, thus enables a highly sophisticated treatment strategy beyond conventional perspective, even for difficult to treat or late stage cancers.

Recommended for: 

• Cancer patient where first-line therapy has failed
• Patients that cancer has relapsed
• Cancer is high-grade / metastatic
• Newly diagnosed patients with difficult cancers such as stomach, oesophagus, pancreas, gall bladder, GIST etc
• Risk of therapy failure is high

Overview

exacta is a comprehensive analysis of tumours that allows a therapy recommendation to be made for most cancer patients, based on clinical evidence and experience. Especially for rare solid tumours where no guidelines are available, in the advanced situation or for tumours that are difficult to treat, exacta is providing an advantage.

exacta analyses millions of data points at the molecular level to identify all relevant targets for an individual therapy.

• exacta® identifies possible molecular targets and cell cycle pathways to find the most appropriate molecular targets for targeted therapy
• Comprehensive exacta® includes chemosensitivity testing for cytotoxic drug efficacy prediction
• exacta® can explore all possible therapeutic options (Drug Repurposing) by analysing all molecular alterations
• Comprehensive exacta® enables effective tumour burden monitoring, therapy response monitoring and helps detect early therapy failure or recurrence.
• exacta® analysis provides therapy recommendation to treating physician

Methodology and Markers

Tumour DNA analysis: 452 genes ( tissue biopsy ) / 411 genes ( liquid biopsy )

Mutations and Gene Amplifications

Fusion / Rearrangements: 51 genes (tissue biopsy) / 12 genes (liquid biopsy)

Tumour Gene Expression: 20.805 genes

Cellular pathways as per KEGG

Chemosensitivity: up to 100 drugs (Subject to availability of adequate sample)

Liquid Biopsy Cell free DNA (cfDNA)

ICC Immunocytochemistry (mTOR, VEGFR, EGFR, etc.)

Microsatellite Instability (MSI / MMR): Tissue biopsy / liquid biopsy

Tumour Mutation Burden (TMB)

Relevant IHC PD-L1, AR: Tissue biopsy

Circulating Tumor Cells (CTCs)

Platforms: NGS, Microscopy, Arrays, ddPCR, CE

Therapy Recommendations (TR)

Pharmacogenetic Guidance

Immunotherapy Guidance

Sanger Sequencing to rule out germline nature of high MAF alterations

Sensitive ddPCR assays to detect therapy relevant low MAF alterations

Longitudinal Monitoring for MAF Comparisons of Repeat Tests

Practical

Specimen

Whole blood

Alternative: FFPE tissue block

Container

• 1x  DCGL tube  
• 1 x EDTA tubes

Volume

20 mL

Patient preparation

Not received blood transfusion at least 10 days prior to collection of sample.

Not chemotherapy/PET-CT/MRI 24 hours before sampling blood

Not positive for HIV / HBV / HCV.